Drug-drug Interaction Articles


  • Anticholinergic/Antimuscarinic Drug Prescribing for OAB: Caution is Needed

    The possibility of drug–drug interactions is an important consideration with any medication, and particularly important in the older adult who are more likely to be using multiple medications. Also, this group is more likely to be taking other anticholinergic medications, and this “anticholinergic load” (the cumulative effect of taking multiple medications that have anticholinergic side effects) may potentiate the number and severity of side effects. Given the importance of the cholinergic system in cognition, direct impairment of cholinergic neurons may be the cause of these effects. In many older adults, OAB drug AC effects on cognition may go undetected.  

    Published August 2, 2016
  • Drug-Drug Interactions in Prostate Cancer Treatment.

    Polypharmacy is associated with an increased risk of drug-drug interactions (DDIs), which can cause serious and debilitating drug-induced adverse events. With a steadily aging population and associated increasing multimorbidity and polypharmacy, the potential for DDIs becomes considerably important.

    Published November 6, 2019
  • High Prevalence of Potential Drug-Drug Interactions in Patients with Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate: Beyond the Abstract

    Abiraterone acetate (AA) is an oral anticancer agent used to treat metastatic castration resistant prostate cancer (mCRPC); clinically functioning to extend patient survival, and defer disease progression and symptoms1,2. By inhibiting cytochrome P450 (CYP) 17A1, AA prevents androgen biosynthesis3,4, while also serving to strongly inhibit CYP1A2, CYP2D6, and CYP2C8, and to moderately inhibit CYP3A4/5, CYP2C9, and CYP2C8. Given an increase in the prescription of oral anticancer agents5, and the typically elderly poly-morbid mCRPC patient population, there are heightened concerns regarding the potential of drug-drug interactions (DDIs) for men treated with AA. Specifically, DDIs may hinder the treatment efficacy of AA, or increase the risk of DDI associated adverse events (AEs). As up to 4% of patients with cancer are believed to experience fatal DDIs6, the primary aim of our retrospective review was to determine the frequency and severity of DDIs for mCRPC patients treated with AA.
    Published November 22, 2016
  • Inhibition of OCT2, MATE1 and MATE2-K as a possible mechanism of drug interaction between pazopanib and cisplatin.

    We hypothesized that pazopanib is an inhibitor of cisplatin renal transporters OCT2, MATE1 and MATE2-K based on previous studies demonstrating an interaction between tyrosine kinase inhibitors and these transporters.

    Published May 19, 2016
  • Optimized Combination of HDACI and TKI Efficiently Inhibits Metabolic Activity in Renal Cell Carcinoma and Overcomes Sunitinib Resistance.

    Clear cell renal cell carcinoma (ccRCC) is characterized by high histone deacetylase (HDAC) activity triggering both cell motility and the development of metastasis. Therefore, there is an unmet need to establish innovative strategies to advance the use of HDAC inhibitors (HDACIs).

    Published November 3, 2020
  • Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer.

    Coadministration of docetaxel and abiraterone acetate plus prednisone (AA + P) may benefit patients with metastatic castration-resistant prostate cancer (mCRPC) because of complementary mechanisms of action.

    Published February 25, 2016